Form 4: Travere Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Jeffrey A Meckler, a Director of Travere Therapeutics, Inc., sold 20,000 shares of common stock on September 10, 2026.
Summary
- Option exercise/conversion: acquired 10,000 Common Stock at $17.44 ($174,400) on September 10, 2026; holds 101,500 after (Direct).
- Option exercise/conversion: acquired 10,000 Common Stock at $26.52 ($265,200) on September 10, 2026; holds 111,500 after (Direct).
- Open-market sale: disposed of 1,700 Common Stock at $65.39 ($111,166) on September 10, 2026; holds 109,800 after (Direct).
- Open-market sale: disposed of 1,200 Common Stock at $66.15 ($79,380) on September 10, 2026; holds 108,600 after (Direct).
- Open-market sale: disposed of 14,000 Common Stock at $67.46 ($944,488) on September 10, 2026; holds 94,600 after (Direct).
- Open-market sale: disposed of 3,100 Common Stock at $68.09 ($211,073) on September 10, 2026; holds 91,500 after (Direct).
- Option exercise/conversion: disposed of 10,000 Stock option (right to buy) on September 10, 2026 (Direct).
- Option exercise/conversion: disposed of 10,000 Stock option (right to buy) on September 10, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,346,106 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jeffrey A Meckler — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Option exercise/conversion | Common Stock | 10,000 | $17 | $174.4K | 101,500 |
| 2026-09-10 | Option exercise/conversion | Common Stock | 10,000 | $27 | $265.2K | 111,500 |
| 2026-09-10 | Open-market sale | Common Stock | 1,700 | $65 | $111.2K | 109,800 |
| 2026-09-10 | Open-market sale | Common Stock | 1,200 | $66 | $79.4K | 108,600 |
| 2026-09-10 | Open-market sale | Common Stock | 14,000 | $67 | $944.5K | 94,600 |
| 2026-09-10 | Open-market sale | Common Stock | 3,100 | $68 | $211.1K | 91,500 |
| 2026-09-10 | Option exercise/conversion | Stock option (right to buy) | 10,000 | — | — | 0 |
| 2026-09-10 | Option exercise/conversion | Stock option (right to buy) | 10,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Option exercise/conversion (10,000 shares) |
| 2026-09-10 | Option exercise/conversion (10,000 shares) |
| 2026-09-10 | Open-market sale (1,700 shares) |
| 2026-09-10 | Open-market sale (1,200 shares) |
| 2026-09-10 | Open-market sale (14,000 shares) |
| 2026-09-10 | Open-market sale (3,100 shares) |
| 2026-09-10 | Option exercise/conversion (10,000 shares) |
| 2026-09-10 | Option exercise/conversion (10,000 shares) |
Keywords
insider transaction, Form 4, TVTX, Travere Therapeutics, Inc., bearish, Jeffrey A Meckler
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.